The putative promotion of triple-negative breast cancer was viewed to arise by Nrf1-mediating proteasomal cytoprotective response to resist against the proteasomal inhibitor treatments 485 and/or Nrf1-driving enhanced expression of programmed death ligand 1 (PD-L1) for its immune evasion 486. This evidence concerns the gene NRF1 and triple-negative breast carcinoma.